TRIAMCINOLONE ACETONIDE | N018117 | ABBVIE INC
| Trial | Phase | Status | Sponsor | Enrollment | Dates |
|---|---|---|---|---|---|
| Phase 2 | Active | Memorial Sloan Kettering Cancer Center | 48 | 2020-07-09 → 2027-07 | |
| Phase 4 | Active | The Cleveland Clinic | 150 | 2021-05-27 → 2027-08-01 | |
| N/A | Not Yet Recruiting | University of California, Davis | 65 | 2026-08-22 → 2028-07-10 | |
| Phase 4 | Not Yet Recruiting | Noor Aziz | 50 | 2026-10-01 → 2027-04-30 | |
| N/A | Not Yet Recruiting | Allama Iqbal Medical College | 60 | 2027-01-01 → 2029-01-01 | |
| Phase 1/2 | Not Yet Recruiting | Shifa International Hospital | 125 | 2026-08-10 → 2027-01-30 | |
| Phase 4 | Recruiting | Massachusetts Eye and Ear Infirmary | 168 | 2022-07-25 → 2027-01-30 | |
| Phase 3 | Recruiting | University of Washington | 120 | 2013-12 → 2026-07 | |
| Phase 4 | Recruiting | Wake Forest University Health Sciences | 250 | 2018-04-30 → 2027-03 | |
| Phase 2 | Recruiting | Deraya University | 50 | 2026-05-01 → 2027-06-01 |
Source: ClinicalTrials.gov. Trials matched by ingredient name; data refreshed each weekday and may lag the registry.
11 active API suppliers hold Drug Master Files for this ingredient.
Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.
| Date | Submission | Document |
|---|---|---|
| Mar 17, 2008 | SUPPL -42 | View Letter (PDF) |
| Apr 20, 2007 | SUPPL -30 | View Letter (PDF) |
| Sep 18, 2006 | SUPPL -37 | View Letter (PDF) |
| Jan 9, 2004 | SUPPL -34 | View Letter (PDF) |
| Dec 23, 2003 | SUPPL -33 | View Letter (PDF) |
| Sep 25, 2003 | SUPPL -32 | View Letter (PDF) |
Source: Drugs@FDA application documents.
No patent or exclusivity listings for this strength.